Comparing the efficacy of regen-cov, remdesivir, and favipiravir in reducing invasive mechanical ventilation need in hospitalized COVID-19 patients

Table 4 The Significance of differences in baseline characteristics between the three groups

Variables	Intervention
	Casirivimab/Imdevimab(A)	Remdesivir (B)	Favipiravir (C)	P valuea
PaO2/FiO2 on day 3	298.57 ± 211.3	154.14 ± 138.9	166.96 ± 130	0
B and C				0.478
A and C				0
A and B				0
PaO2/FiO2 on day 7	320.62 ± 93.64	163.55 ± 172.6	178.59 ± 138	0
B and C				0.413
A and C				0
A and B				0
PaO2/FiO2 on day 14	389.75 ± 51.93	154.67 ± 174	165.2 ± 98.87	0.005
B and C				0.155
A and C				0.022
A and B				0.001
PaO2/FiO2 on day 28		172.75 ± 181	53 ± 0	0.48
B and C				NA
Need for IMV				0.005
Yes	1/53	22/106	22/106
No	52/53	84/106	84/106
B and C				1
A and C				0.003
A and B				0.003
Duration of need for O2 therapy and IMV	3.72 ± 3.527	9.2 ± 7.107	7.46 ± 5.077	0
B and C				0.119
A and C				0
A and B				0

^aP < 0.05 is considered a statistically significant difference between the compared groups. (1) Comparing between the three groups (A, B, C); (2) A pairwise comparison between every 2 groups (A-B, B-C, A-C), if there is a statistically significant difference between the three groups as presented by the comparing between the three groups (A, B, C); NA: Not available. IMV: Invasive mechanical ventilation.